Shattuck Labs (NASDAQ:STTK) Earns “Neutral” Rating from HC Wainwright

HC Wainwright reaffirmed their neutral rating on shares of Shattuck Labs (NASDAQ:STTK) in a research report sent to investors on Thursday morning,Benzinga reports.

Other equities research analysts also recently issued research reports about the stock. Leerink Partnrs upgraded shares of Shattuck Labs to a “strong-buy” rating in a research note on Monday, March 17th. Leerink Partners initiated coverage on shares of Shattuck Labs in a report on Monday, March 17th. They issued an “outperform” rating and a $4.00 price target for the company. Four investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

Shattuck Labs Price Performance

STTK stock opened at $1.06 on Thursday. The stock has a market capitalization of $50.37 million, a price-to-earnings ratio of -0.69 and a beta of 1.66. The company has a 50-day moving average of $1.24 and a two-hundred day moving average of $1.48. Shattuck Labs has a 52-week low of $0.94 and a 52-week high of $11.76.

Shattuck Labs (NASDAQ:STTK) last posted its quarterly earnings data on Thursday, March 27th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.01. Shattuck Labs had a negative return on equity of 61.92% and a negative net margin of 1,156.46%. Equities analysts expect that Shattuck Labs will post -1.48 EPS for the current fiscal year.

Institutional Trading of Shattuck Labs

Institutional investors and hedge funds have recently modified their holdings of the company. Adage Capital Partners GP L.L.C. boosted its stake in Shattuck Labs by 61.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 4,675,000 shares of the company’s stock worth $5,657,000 after buying an additional 1,775,000 shares in the last quarter. 683 Capital Management LLC acquired a new stake in shares of Shattuck Labs during the 4th quarter valued at about $1,270,000. Prosight Management LP increased its stake in Shattuck Labs by 15.1% in the fourth quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock valued at $8,033,000 after acquiring an additional 873,409 shares during the period. Takeda Pharmaceutical Co. Ltd. acquired a new position in Shattuck Labs in the fourth quarter worth about $624,000. Finally, Bank of America Corp DE lifted its stake in Shattuck Labs by 135.0% during the fourth quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock worth $226,000 after purchasing an additional 107,491 shares during the period. 58.74% of the stock is currently owned by institutional investors.

About Shattuck Labs

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.